Compositions comprising 6,7-dihydroxybergamottin (6,7-DHB) and quercetin wherein the bioavailability of quercetin is enhanced as a result of the inhibition of cytochrome P450 enzymes from 6,7-DHB. The compositions are also used in methods of treating cancer, inflammation, cardiovascular disease, hypertension, polycystic ovary syndrome, a neurodegenerative disease, an infection or for enhancing cellular zinc uptake.

Compositions comprising 6,7-dihydroxybergamottin (6,7-DHB) and quercetin wherein the bioavailability of quercetin is enhanced as a result of the inhibition of cytochrome P450 enzymes from 6,7-DHB. The compositions are also used in methods of treating cancer, inflammation, cardiovascular disease, hypertension, polycystic ovary syndrome, a neurodegenerative disease, an infection or for enhancing cellular zinc uptake.

Compositions comprising 6,7-dihydroxybergamottin (6,7-DHB) and quercetin wherein the bioavailability of quercetin is enhanced as a result of the inhibition of cytochrome P450 enzymes from 6,7-DHB. The compositions are also used in methods of treating cancer, inflammation, cardiovascular disease, hypertension, polycystic ovary syndrome, a neurodegenerative disease, an infection or for enhancing cellular zinc uptake.

The disclosure provides a method of inhibiting proliferation of a cell, inhibiting m3C formation in a cell, inhibiting activity of Mettl8 in a cell, or activating ATM and p53 in a cell, the method comprising contacting the cell with a Mettl8 inhibitor. The disclosure also provides a composition comprising a cell with a reduced expression or activity of Mettl8. In another aspect, the disclosure provides methods of rendering a tumor cell sensitive to a cancer therapy.

The disclosure provides a method of inhibiting proliferation of a cell, inhibiting m3C formation in a cell, inhibiting activity of Mettl8 in a cell, or activating ATM and p53 in a cell, the method comprising contacting the cell with a Mettl8 inhibitor. The disclosure also provides a composition comprising a cell with a reduced expression or activity of Mettl8. In another aspect, the disclosure provides methods of rendering a tumor cell sensitive to a cancer therapy.

The present invention is a method and composition for the treatment of skin conditions where the epidermal barrier has decreased function such as when the patient is suffering from eczema, in particular, Atopic Dermatitis. Epidermal barrier function can be significantly improved and the extraction of epidermal lipids can be reduced by using formulations containing high Krafft temperature surfactants, preferably, anionic surfactants.

The present invention is a method and composition for the treatment of skin conditions where the epidermal barrier has decreased function such as when the patient is suffering from eczema, in particular, Atopic Dermatitis. Epidermal barrier function can be significantly improved and the extraction of epidermal lipids can be reduced by using formulations containing high Krafft temperature surfactants, preferably, anionic surfactants.

Method and pharmaceutical compositions for treating or limiting the occurrence of viral infections by administering a therapeutically effective amount of a pharmaceutical composition that targets the ACE2 active site. The pharmaceutical compositions include those of Formula (I), Formula (II), Formula (III), including Formulas (IIIa) and (IIIb), and the viral infections including but not limited to respiratory viruses and disease conditions and syndromes that are associated with the viral infections.

Method and pharmaceutical compositions for treating or limiting the occurrence of viral infections by administering a therapeutically effective amount of a pharmaceutical composition that targets the ACE2 active site. The pharmaceutical compositions include those of Formula (I), Formula (II), Formula (III), including Formulas (IIIa) and (IIIb), and the viral infections including but not limited to respiratory viruses and disease conditions and syndromes that are associated with the viral infections.

Method and pharmaceutical compositions for treating or limiting the occurrence of viral infections by administering a therapeutically effective amount of a pharmaceutical composition that targets the ACE2 active site. The pharmaceutical compositions include those of Formula (I), Formula (II), Formula (III), including Formulas (IIIa) and (IIIb), and the viral infections including but not limited to respiratory viruses and disease conditions and syndromes that are associated with the viral infections.